Social enterprise accelerator for health innovators kicks-off in Nairobi - Capital Business
Connect with us

Hi, what are you looking for?

Enterprise

Social enterprise accelerator for health innovators kicks-off in Nairobi

NAIROBI, Kenya, Jun 13 – ‘Making More Health’ is a program aimed at helping social entrepreneurs in the health sector scale their solutions across Sub-Saharan Africa.

The program has kicked off here in Nairobi with a co-creation workshop which will culminate to the Making More Health (MMH) Accelerator.

The program – sponsored by global pharmaceutical company, Boehringer Ingelheim, and Ashoka, a network of social entrepreneurs – brings together some of the best experiences in social innovation and global health to improve access to healthcare systems across Sub-Saharan Africa.

Along with capacity building as well as technical and financial support to develop, pilot and test their co-creation ideas, the social entrepreneurs participating in the program will receive training on business model innovation, market strategy and scaling models.

Simon Manyara, Access to Healthcare Manager at Boehringer Ingelheim says the co-creation thinking workshops will help address the most critical topics in health care.

“We want to foster local social innovation and increase access to healthcare among underserved communities and strengthen the potential of these projects through the immense knowledge pool within our talent and global operations network,” explains Manyara.

Through the accelerator process, social entrepreneurs participating in the Accelerator will have access to a network of professional support, including Boehringer Ingelheim and Ashoka experts.

The MMH Accelerator combines Ashoka’s expertise in social entrepreneurship with the pharmaceutical’s business acumen and knowledge of the healthcare industry.

The participating projects address several themes such as providing medical care in remote areas in a more effective and sustainable manner, digital platforms that support integrated care for patients with chronic diseases, and increasing transparency within the pharmaceutical supply chain.

Advertisement. Scroll to continue reading.
Advertisement

More on Capital Business